ADVENTRX to Present at 6th Annual Fortis Bank Biotechnology Conference
April 13 2006 - 12:00PM
PR Newswire (US)
SAN DIEGO, April 13 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that it has
accepted an invitation to present at the 6th Annual Fortis Bank
Biotechnology Conference on Wednesday, April 26, 2006 at 2:45 p.m.
British Standard Time at the Four Seasons Hotel, Park Lane, London.
The Company's presentation will feature details regarding its
extended product portfolio, including newly licensed compounds
pursuant to a definitive merger agreement with SD Pharmaceuticals
which was announced April 10, 2006. In addition, the Company will
report progress on its CoFactor(R) oncology and Thiovir(TM)
antiviral clinical programs. About ADVENTRX ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on introducing new anticancer and antiviral
treatments that surpass the performance and safety of existing
drugs, by addressing significant problems such as drug metabolism,
toxicity, bioavailability and resistance. More information can be
found on the Company's Web site at http://www.adventrx.com/.
Forward-Looking Statement This press release contains
forward-looking statements, within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
regarding ADVENTRX. Such statements are made based on management's
current expectations and beliefs. Actual results may vary from
those currently anticipated based upon a number of factors,
including uncertainties inherent in the drug development process,
the timing and success of clinical trials, the validity of research
results, and the receipt of necessary approvals from the FDA and
other regulatory agencies. For a discussion of such risks and
uncertainties, which could cause actual results to differ from
those contained in the forward-looking statements regarding
ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last
annual report on Form 10-K, as well as other reports that ADVENTRX
files from time to time with the Securities and Exchange
Commission. All forward-looking statements regarding ADVENTRX are
qualified in their entirety by this cautionary statement. ADVENTRX
undertakes no obligation to release publicly any revisions, which
may be made to reflect events or circumstances after the date
hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea
Lynn of ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024